Home > Cardiology > AHA 2019 > New Frontiers in Lipid Therapy > Icosapent ethyl plus statins reduces total plaque volume

Icosapent ethyl plus statins reduces total plaque volume

Presented By
Prof. Matthew J. Budoff, UCLA, USA
Conference
AHA 2019
Trial
EVAPORATE
The pre-specified, interim, 9-month follow-up analysis from the EVAPORATE trial suggests that icosapent ethyl 4 g/day did not reduce low attenuation plaque volume compared with placebo, although it did reduce total plaque volume, as assessed by coronary CT angiography. Prof. Matthew J. Budoff (UCLA, USA) presented the early results from EVAPORATE, which aimed to assess the efficacy of icosapent ethyl in addition to statin therapy in reducing plaque burden among patients with known angiographic coronary artery disease [1]. Patients between 30-85 years of age with persistently high triglycerides (135-499 mg/dL) were randomised 1:1 to either icosapent ethyl 4 g/day (n=40) or placebo (n=40). In each arm, 30% had a family history of coronary artery disease. The primary outcome was the percentage change in low attenuation plaque volume. At 9 months follow-up, the primary outcome was not ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on